| Biomarker ID | 1247 |
| PMID | 24251762 |
| Year | 2013 |
| Biomarker | Anterior gradient 2 [AGR2] |
| Biomarker Basis | Concentration Based |
| Biomolecule | Protein |
| Source | Urine |
| Subjects | Humans |
| Regulation | Upregulated in PCa |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways include: ERN2 human kinase ARCHS4 coexpression, STYK1 human kinase ARCHS4 coexpression, MAPK15 human kinase ARCHS4 coexpression, TNK1 human kinase ARCHS4 coexpression, CDC42BPG human kinase ARCHS4 coexpression |
| Experiment | Prostate Cancer Vs No Prostate Cancer |
| Type of Biomarker | Diagnostic |
| Cohort | 14 patients with Prostate cancer and 23 controls were used for this analysis |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p = 0.026 |
| Method Used | PRISM-SRM |
| Clinical | No |
| Remarks | Biomarker Calculated as AGR2/PSA protein concentration ratio |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | NA |